B7-H3 Antibody Specificity via Sequence Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies directed against B7-H3, such as M3.2D7, fail to specifically bind to the B7-H3 protein, making them unreliable diagnostic reagents for cancer detection and assessing the efficacy of B7-H3 targeted therapies.
Innovation Solution
Development of isolated antibodies with specific heavy and light chain immunoglobulin variable domain sequences that bind to the B7-H3 epitope, including sequences like KHSDSKEDDGQEIA, with high affinity, enabling accurate detection and targeting of B7-H3 in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If commercially available antibodies (e.g., M3.2D7) are used for B7-H3 detection, then the diagnostic process is simplified and readily available, but the binding specificity and reliability are insufficient
Solution Approach 1:
The patent changes the binding parameters of antibodies by selecting and characterizing antibodies with specific EC50 values (at least 6.7×10−11 M) and specific epitope recognition (KHSDSKEDDGQEIA sequence). This parameter-based selection ensures high binding affinity and specificity while maintaining diagnostic reliability.
2Measurement precision
If antibodies with high binding affinity are developed, then detection accuracy is improved, but the complexity of antibody characterization and validation increases
Solution Approach 1:
The patent replaces complex functional validation assays with direct sequence-based identification. By defining specific heavy and light chain immunoglobulin variable domain sequences that confer binding to the KHSDSKEDDGQEIA epitope, the invention simplifies characterization while ensuring high detection accuracy through sequence verification rather than extensive functional testing.
Solution Approach 2:
The patent establishes clear quantitative parameters (EC50 ≥ 6.7×10−11 M) and specific sequence identifiers to define antibody performance. This parameter-based definition streamlines validation by providing objective criteria for antibody selection and characterization, reducing the complexity of verification processes.
3Reliability
If specific epitope recognition is achieved, then diagnostic reliability is improved, but the difficulty of identifying and validating the correct antibody increases
Solution Approach 1:
The patent replaces complex binding assays and validation procedures with direct sequence identification. By specifying the exact heavy and light chain variable domain sequences that recognize the KHSDSKEDDGQEIA epitope, the invention enables straightforward validation through sequence matching, significantly reducing the difficulty of antibody verification while maintaining high specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide reliable binding to B7-H3 with a half maximal effective concentration (EC50) of at least 6.7×10−11 M, facilitating accurate detection in cancer tissues and monitoring of B7-H3 targeted therapies.
Implementation Method 1
the antibody binds to an epitope of human B7-H3 comprising the amino acid sequence KHSDSKEDDGQEIA
Data Source
AI summary
Provided herein are B7-H3 antibodies, fragments of such antibodies, and compositions comprising the same. The antibodies, antibody fragments and compositions are useful in a number of analytical methods, including immunohistochemical and immunocytochemical detection and analysis of B7-H3. Also provided herein are isolated peptides and fusion proteins containing immunogenic determinants for said B7-H3 antibodies, animals immunized with the peptides and fusion proteins, isolated B cells obtained from the animals, and hybridomas made from the isolated B cells.